BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Pharmacy is now the fastest-growing line in most benefits budgets\, driven by specialty therapies\, gene and cell treatments\, and GLP-1 demand. Employers are working both sides of the problem: tightening PBM contracts\, formularies\, and utilization management while deciding which high-demand drugs\, GLP-1s first among them\, earn coverage and on what terms. The line worth drawing is where pharmacy strategy bends the trend and where plan design merely shifts cost onto employees.\n\nThis Session Will Examine:\n\n• Sizing pharmacy exposure before renewal: trend by category (specialty\, biologics\, GLP-1s)\, duration of therapy\, and the discontinuation rates that change the math.\n• PBM contracting and transparency: rebate guarantees\, pass-through pricing\, and the leverage employers have at renewal\, alone or through coalitions.\n• GLP-1 coverage as the visible test: eligibility criteria\, care-program requirements\, emerging buying channels\, and rules that hold up clinically\, financially\, and with employees.\n• Biosimilars\, site-of-care shifts\, and formulary discipline as levers that lower cost without taking benefits away.\n• Measuring what the spend buys: adherence\, health outcomes\, disability and absence\, productivity\, and retention effects beyond the pharmacy line.\n\n
X-ALT-DESC;FMTTYPE=text/html:Pharmacy is now the fastest-growing line in most benefits budgets, driven by specialty therapies, gene and cell treatments, and GLP-1 demand. Employers are working both sides of the problem: tightening PBM contracts, formularies, and utilization management while deciding which high-demand drugs, GLP-1s first among them, earn coverage and on what terms. The line worth drawing is where pharmacy strategy bends the trend and where plan design merely shifts cost onto employees.<br><br><strong>This Session Will Examine:<br /></strong><ul><li>Sizing pharmacy exposure before renewal: trend by category (specialty, biologics, GLP-1s), duration of therapy, and the discontinuation rates that change the math.</li><li>PBM contracting and transparency: rebate guarantees, pass-through pricing, and the leverage employers have at renewal, alone or through coalitions.</li><li>GLP-1 coverage as the visible test: eligibility criteria, care-program requirements, emerging buying channels, and rules that hold up clinically, financially, and with employees.</li><li>Biosimilars, site-of-care shifts, and formulary discipline as levers that lower cost without taking benefits away.</li><li>Measuring what the spend buys: adherence, health outcomes, disability and absence, productivity, and retention effects beyond the pharmacy line.</li></ul>
UID:ed6c933ecf6f43f6a21058e1e1663269addeventcom
SUMMARY:THINK TANK: Pharmacy Spend Under Pressure: Specialty Trend\, GLP-1 Demand\, and PBM Strategy
DTSTART;TZID=America/New_York:20261118T140000
DTEND;TZID=America/New_York:20261118T144500
DTSTAMP:20260723T221342Z
TRANSP:OPAQUE
STATUS:CONFIRMED
SEQUENCE:0
LOCATION:https://us06web.zoom.us/j/2237646017
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
BEGIN:VALARM
TRIGGER:-PT30M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR